Vericel (VCEL) to Release Quarterly Earnings on Thursday

Vericel (NASDAQ:VCEL) is expected to be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Vericel to post earnings of $0.45 per share and revenue of $92.6640 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Vericel Stock Up 1.6%

NASDAQ VCEL opened at $37.41 on Thursday. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of 155.88 and a beta of 1.24. Vericel has a twelve month low of $29.24 and a twelve month high of $58.16. The stock has a fifty day simple moving average of $36.93 and a 200 day simple moving average of $36.08.

Institutional Investors Weigh In On Vericel

A number of large investors have recently bought and sold shares of VCEL. AQR Capital Management LLC acquired a new position in shares of Vericel during the first quarter valued at about $242,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Vericel by 6.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,445 shares of the biotechnology company’s stock valued at $1,403,000 after buying an additional 1,847 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Vericel by 13.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 371,486 shares of the biotechnology company’s stock valued at $16,576,000 after buying an additional 44,333 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Vericel by 9.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,028 shares of the biotechnology company’s stock worth $5,490,000 after buying an additional 10,191 shares during the period. Finally, Qube Research & Technologies Ltd boosted its holdings in Vericel by 5.1% in the second quarter. Qube Research & Technologies Ltd now owns 277,253 shares of the biotechnology company’s stock worth $11,797,000 after acquiring an additional 13,422 shares in the last quarter.

Analysts Set New Price Targets

Several analysts recently commented on the company. Zacks Research cut Vericel from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Wall Street Zen raised shares of Vericel from a “hold” rating to a “buy” rating in a research note on Sunday, January 25th. Truist Financial decreased their price objective on shares of Vericel from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Vericel in a report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Vericel currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.